B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer
Purpose Chimeric antigen receptor T (CAR-T) cell therapy is under clinical investigation in patients with metastatic triple-negative breast cancer (TNBC). However, the identification of targetable antigens remains a high priority to avoid toxicity and prevent tumor escape.Experimental design Here we...
| Published in: | Journal for ImmunoTherapy of Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Online Access: | https://jitc.bmj.com/content/13/5/e011533.full |
